PHARMARON Engages in Multiple Collaborations Across Various Sectors to Advance Business Objectives

Stock News03-12

PHARMARON (03759) has issued an announcement addressing recent media reports concerning a production collaboration between the Group and a Chinese subsidiary of an internationally leading pharmaceutical enterprise. Following reasonable inquiries under the circumstances, the company confirms that the aforementioned production cooperation was established and will be conducted as part of the Group's ordinary and usual business operations. In the course of its daily operations, the Group routinely engages in collaborations with multiple companies across different fields to further its own business development goals. Furthermore, the company is not aware of any information that must be disclosed to prevent a false market in the company's securities, nor is it aware of any inside information requiring disclosure under Rule 13.09(2) of the Listing Rules and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188930780?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188930780","market":"hk","top_or_hot":-1,"title":"PHARMARON Engages in Multiple Collaborations Across Various Sectors to Advance Business Objectives","media":"Stock News","content":"<p>PHARMARON (03759) has issued an announcement addressing recent media reports concerning a production collaboration between the Group and a Chinese subsidiary of an internationally leading pharmaceutical enterprise. Following reasonable inquiries under the circumstances, the company confirms that the aforementioned production cooperation was established and will be conducted as part of the Group's ordinary and usual business operations. In the course of its daily operations, the Group routinely engages in collaborations with multiple companies across different fields to further its own business development goals. Furthermore, the company is not aware of any information that must be disclosed to prevent a false market in the company's securities, nor is it aware of any inside information requiring disclosure under Rule 13.09(2) of the Listing Rules and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PHARMARON Engages in Multiple Collaborations Across Various Sectors to Advance Business Objectives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPHARMARON Engages in Multiple Collaborations Across Various Sectors to Advance Business Objectives\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-12 20:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PHARMARON (03759) has issued an announcement addressing recent media reports concerning a production collaboration between the Group and a Chinese subsidiary of an internationally leading pharmaceutical enterprise. Following reasonable inquiries under the circumstances, the company confirms that the aforementioned production cooperation was established and will be conducted as part of the Group's ordinary and usual business operations. In the course of its daily operations, the Group routinely engages in collaborations with multiple companies across different fields to further its own business development goals. Furthermore, the company is not aware of any information that must be disclosed to prevent a false market in the company's securities, nor is it aware of any inside information requiring disclosure under Rule 13.09(2) of the Listing Rules and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1188930780","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188930780","pubTimestamp":1773319102,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"PHARMARON (03759) has issued an announcement addressing recent media reports concerning a production collaboration between the Group and a Chinese subsidiary of an internationally leading...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300759":"康龙化成","BK1141":"生命科学工具和服务","03759":"康龙化成","BK0216":"研究试验","BK1576":"医药外包概念"},"translate_title":"康龙化成参与多个行业的多项合作，以推进业务目标","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300759":1,"03759":1},"content_text":"PHARMARON (03759) has issued an announcement addressing recent media reports concerning a production collaboration between the Group and a Chinese subsidiary of an internationally leading pharmaceutical enterprise. Following reasonable inquiries under the circumstances, the company confirms that the aforementioned production cooperation was established and will be conducted as part of the Group's ordinary and usual business operations. In the course of its daily operations, the Group routinely engages in collaborations with multiple companies across different fields to further its own business development goals. Furthermore, the company is not aware of any information that must be disclosed to prevent a false market in the company's securities, nor is it aware of any inside information requiring disclosure under Rule 13.09(2) of the Listing Rules and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188930780","isCrawlerRequest":true}